What is pathophysiology of Alzheimer?

['Iscurtade custa pàgina']

Cale est sa fisiopatologia de s'Alzheimer?

Sa fisiopatologia de sa maladia de Alzheimer (MA) est unu protzessu cumplessu chi ìmplicat s'ammuntonamentu de proteinas anormales, infiammamentu e disfunzione neuronale.

Sos duos printzipales sinnos de sa maladia de Alzheimer sunt sa presèntzia de placas de amiloide-beta (Aβ) e sos grovos neurofibrillares (NFT) in su cherbeddu.

Sas placas de amiloide-beta si formant cando sos frammentos de sa proteina precursora de s'amiloide (APP) sunt segados dae sos enzimas pro formare sos peptides Aβ.

Custos peptides s'aggregant e formant fibrillas insolùbiles chi s'ammuntonant in foras de sos neurones, interrùmpende sa comunicatzione tra tzèllulas e giughende a sa morte neuronale.

S'ammuntonamentu de placas de Aβ si pensat chi siat unu de sos primos eventos in s'isvilupu de sa maladia de Alzheimer, e si pensat chi contribuat a su protzessu neurodegenerativu.

Sos grovos neurofibrillares si formant cando sa proteina tau si faghet iperfosforilada e format filamentos anormales a intro de sos neurones.

Custos grovos interrumpent su funtzionamentu normale de sos microtùbulos, chi sunt essentziales pro su trasportu de nutrientes e àteros materiales a intro de su neurone.

Sos ligàmenes a sa fine batint a sa morte de sos neurones interessados.

S'inflamatzione giogat fintzas unu ruolu in sa fisiopatologia de sa maladia de Alzheimer.

Su sistema immunitàriu rispondet a s'ammuntonamentu de placas Aβ e NFTs cun sa liberatzione de citocinas pro-inflamatòrias, chi podent aumentare sos dannos a sos neurones.

In prus, b'at proas chi s'istress ossidativu, sa disfuntzione mitocondriale e su metabolismu de su glucosiu diminuidu contribuint a sa fisiopatologia de sa MA.

Custos fatores podent batire a una disfunzione e morte neuronale, agravende in manera annanghedora su protzessu de sa maladia.

In generale, sa fisiopatologia de sa maladia de Alzheimer est un'interatzione cumplessa de fatores mùltiplos chi a sa fine batint a su declinu progressivu de sa funtzione cognitiva e a sa pèrdida de memòria chi caraterizat sa maladia.

['Referèntzias']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Disclaimer: mèdicu']

['Custu giassu est fatu po istudiare e informae sa zente e non est unu giassu de consultatzione o de azudu.']

['Sa informassione frunida no est de impreare pro diagnosticare o curare unu problema de salude o una maladia, e sos chi chircant consìgios mèdicos personales si depent cuntatare cun unu mèdicu autorizadu.']

["S'arricordaus ca sa retza neurali chi creat rispostas a is pregontas est imperfeta candu si chistionat de nùmerus, po nai su nùmeru de personas chi tenint una maladia."]

["Chirca semper su parre de su dotore tuo o de un'àteru dotore cualificadu pro cale si siat cunditzione mèiga. No disconnoscas mai su parre de unu professionista mèigu o non bi tardes a l'agatare pro carchi cosa chi as lèghidu in custu situ. Si tenes pensamentos de tènnere un'emergèntzia mèiga, telefona a su 911 o bae a su pronto soccorsu prus acanta."]

['Disclaimer: deretu de autore']

['Sa Digital Millennium Copyright Act de su 1998, 17 U.S.C. § 512 (sa DMCA) donat unu recursu a is propietàrius de deretus de autori chi pensant chi unu materiali chi aparit in Internet ofendet is deretus insoru assuta de sa lei de su deretu de autori de is IUA. ']

["Si creis de bona fidi chi calicunu cuntènniu o materiale postu a disponimentu in su giassu o in is servìtzios nostros at ofesu is deretus de autore tuos, tui (o s'agenti tuo) nos podes imbiare una comunicatzioni domandendi de nde bogare su cuntènniu o su materiale, o de nde blocare s'atzessu."]

['Sos annùntzios depent èssere imbiados pro iscrittu pro mèdiu de posta eletrònica (càstia sa setzione "Cuntatu" pro s\'indiritzu de posta eletrònica). ']

["Sa DMCA recheret chi sa notìfica tua de sa presunta violatzione de copyright incluat sas informatziones sighentes: (1) descritzione de s'òpera amparada dae copyright chi est ogetu de sa presunta violatzione; (2) descritzione de su chi si narat chi est unu cuntènnidu chi diat pòdere èssere istadu violadu e informatziones bastantes pro nos permìtere de localizare su cuntènnidu; (3) informatziones pro ti cuntatare, intre cales s'indiritzu tuo, su nùmeru de telèfono e s'indiritzu de posta eletrònica; (4) una decraratzione tua pro nàrrere chi tenes bona fide chi su cuntènnidu de sa manera chi ses lamentende non est autorizadu dae su mere de su copyright, dae s'agente suo o dae cale si siat lege."]

["5) una decraratzione firma tua, suta pena de perjuria, chi is informatziones in sa notìfica sunt acuradas e chi tenes s'autorizatzione pro aplicare is deretos de autore chi sunt istados violados; "]

['e (6) una firma fìsica o eletrònica de su mere de su deretu de autore o de una persone autorizada a agire a nùmene suo. ']

['Si non ponis totu is informatzionis de prima podit essi chi su protzedimentu ti siat tardau.']

['Contatu']

['Manda·nos una mail cun cale si siat dimanda o sugerimentu.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.